7,250,000 Shares CEREVEL THERAPEUTICS HOLDINGS, INC. COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENTUnderwriting Agreement • August 12th, 2022 • Cerevel Therapeutics Holdings, Inc. • Pharmaceutical preparations • New York
Cerevel Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom each of Morgan Stanley & Co. LLC (“Morgan Stanley”), Goldman Sachs & Co. LLC (“Goldman”), Jefferies LLC (“Jefferies”) and Evercore Group L.L.C. (“Evercore”) is acting as representative (each of Morgan Stanley, Goldman, Jefferies and Evercore, a “Representative” and collectively, the “Representatives”), 7,250,000 shares of its common stock, par value $0.0001 per share set forth in Schedule II hereto (the “Firm Shares”). The Company also proposes to issue and sell to the several Underwriters not more than an additional 1,087,500 shares of its common stock, par value $0.0001 per share set forth in Schedule II hereto (the “Additional Shares”) if and to the extent that the Representatives shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of common stock g
